Harmony Infra Ventures Bets ₹800 Crore on Luxury Housing Surge in Ghaziabad
Source: Economictimes
Arth Insight · What this means for your wallet
- Harmony Infra Ventures is investing ₹800 crore in a luxury project in Indirapuram, Ghaziabad.
- Individual units are priced at a premium range of ₹6 crore to ₹7.5 crore.
- Strong demand is evident with nearly 40% of the inventory sold shortly after launch.
Wealth-Impact Simulator
See how a change in interest rates hits your loan EMI.
Indicative estimate for education only — not investment advice.
Compare loan ratesReal estate developer Harmony Infra Ventures is investing ₹800 crore to develop 'The Horizon Residences,' a premium housing project in Indirapuram. With units priced up to ₹7.5 crore, the project highlights a growing appetite for luxury living in the Delhi-NCR region.
- ▸Harmony Infra Ventures is investing ₹800 crore in a luxury project in Indirapuram, Ghaziabad.
- ▸Individual units are priced at a premium range of ₹6 crore to ₹7.5 crore.
- ▸Strong demand is evident with nearly 40% of the inventory sold shortly after launch.
- ▸The developer projects a total revenue of ₹1,600 crore by the time the project is completed in 2030.
- ✓Harmony Infra Ventures is investing ₹800 crore in a luxury project in Indirapuram, Ghaziabad.
- ✓Individual units are priced at a premium range of ₹6 crore to ₹7.5 crore.
- ✓Strong demand is evident with nearly 40% of the inventory sold shortly after launch.
- ✓The developer projects a total revenue of ₹1,600 crore by the time the project is completed in 2030.
The real estate landscape in the Delhi-NCR region is witnessing a significant shift as luxury housing moves beyond traditional hubs like Gurugram and South Delhi. Harmony Infra Ventures has announced a major investment of ₹800 crore to develop 'The Horizon Residences,' an upscale residential project located in Indirapuram, Ghaziabad.
High Stakes in Indirapuram
The project represents a bold move into the high-ticket segment for the area, featuring a limited collection of 264 luxury units. Reflecting the premium nature of the development, price points are set between ₹6 crore and ₹7.5 crore per unit. Despite these high price tags, early market response has been robust, with approximately 100 units—nearly 38% of the total inventory—already sold out.
This rapid absorption of high-value units signals a fundamental change in buyer behavior in Ghaziabad. Historically known for affordable and mid-segment housing, Indirapuram is now emerging as a preferred destination for affluent investors and end-users seeking premium amenities and exclusivity.
Financial Outlook and Timelines
Harmony Infra Ventures expects the project to generate a total revenue of ₹1,600 crore, effectively doubling its initial investment. The developer has set a completion deadline for the year 2030, aligning with the long-term infrastructure growth projected for the NCR region.
- Investment: ₹800 crore
- Expected Revenue: ₹1,600 crore
- Total Units: 264 luxury residences
- Completion Goal: 2030
A Shift in NCR Real Estate Dynamics
The success of early sales at The Horizon Residences underscores a broader trend across the National Capital Region. As land prices rise and infrastructure improves, developers are increasingly focusing on the "luxury" and "ultra-luxury" categories. Buyers are showing a willingness to pay a premium for larger floor plans, better security, and modern lifestyle facilities, even in areas previously considered secondary markets.
For retail investors and homebuyers, this development serves as a marker for the rising valuation of property in the eastern fringes of the NCR. As the project progresses toward its 2030 completion date, it is expected to set a new benchmark for residential pricing in the Ghaziabad-Noida belt.
Real estate investments carry inherent risks; readers are advised to verify RERA credentials and project details independently before making any financial commitments.
Community Pulse · This story
How readers rate the outlook after reading this article. Anonymous · one vote per reader · updates live.
Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.
Frequently Asked Questions
Where is the new luxury project located?
The project, named The Horizon Residences, is located in the Indirapuram area of Ghaziabad within the Delhi-NCR region.
What is the starting price for a home in this project?
Prices for the luxury units in this development start at ₹6 crore and go up to ₹7.5 crore.
When will the construction be completed?
Harmony Infra Ventures expects to complete the project and hand over possession by the year 2030.
Join the Arth Vani channels
Daily news summaries, IPO & market alerts on Telegram and WhatsApp.
Because you read about real-estate
Govt to Ban Drugmakers for Mislabeling and Fraudulent Approvals Under New Rules
The Union Health Ministry has amended the Drugs Rules, 1945, to strictly bar pharmaceutical companies from selling products approved through false information. The new regulations empower authorities to debar manufacturers and distributors to ensure medicine safety for Indian consumers.
Indian Pharma Alliance Urges Regularisation for Decade-Old Unapproved Drugs
The Indian Pharmaceutical Alliance (IPA) is pushing drug authorities to regularise numerous 'legacy drugs' that have been sold in the market for over a decade without central regulatory approval. This move aims to close long-standing regulatory gaps affecting common medicines like sodium valproate and carbamazepine tablets.
Takeda's Qdenga Dengue Vaccine Approved in India, Commercial Launch Expected 2027
Takeda Pharmaceutical's new dengue vaccine, Qdenga, has received approval in India. The vaccine is slated for commercial launch in early 2027, initially targeting the private market for individuals before potential government procurement.
Related Stories
Govt to Ban Drugmakers for Mislabeling and Fraudulent Approvals Under New Rules
The Union Health Ministry has amended the Drugs Rules, 1945, to strictly bar pharmaceutical companies from selling products approved through false information. The new regulations empower authorities to debar manufacturers and distributors to ensure medicine safety for Indian consumers.
Indian Pharma Alliance Urges Regularisation for Decade-Old Unapproved Drugs
The Indian Pharmaceutical Alliance (IPA) is pushing drug authorities to regularise numerous 'legacy drugs' that have been sold in the market for over a decade without central regulatory approval. This move aims to close long-standing regulatory gaps affecting common medicines like sodium valproate and carbamazepine tablets.
Takeda's Qdenga Dengue Vaccine Approved in India, Commercial Launch Expected 2027
Takeda Pharmaceutical's new dengue vaccine, Qdenga, has received approval in India. The vaccine is slated for commercial launch in early 2027, initially targeting the private market for individuals before potential government procurement.
BreakingGovernment Considers National Safety Framework for Dental Implants
India's government is exploring a national regulatory framework for dental implants to address concerns over unregulated use and ensure patient safety. This initiative aims to standardize the manufacturing, sale, and clinical application of these medical devices across the country.